Processa Pharmaceuticals
PCSA
18 hedge funds and large institutions have $691K invested in Processa Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 6 closing their positions.
1.08% less ownership
Funds ownership: 6.74% → 5.67% (-1.1%)
18% less funds holding
Funds holding: 22 → 18 (-4)
19% less capital invested
Capital invested by funds: $853K → $691K (-$161K)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$167K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$16.5K |
| 3 |
Renaissance Technologies
New York
|
+$8.57K |
| 4 |
VF
Virtu Financial
New York
|
+$7.97K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$217K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$30.7K |
| 3 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$24.5K |
| 4 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$23K |
| 5 |
BlackRock
New York
|
-$17.1K |
PCSA Hedge Fund Activity: Q2 2023 in Review
18 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Processa Pharmaceuticals (PCSA) for Q2 2023, worth a combined $691K — down 19% from $853K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of PCSA and 2 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 2 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $167K. The largest seller was Walleye Capital, cutting an estimated $217K.
- 18 institutional investors held Processa Pharmaceuticals (PCSA) as of Q2 2023, down from 22 in Q1 2023.
- Funds reported $691K of Processa Pharmaceuticals stock for Q2 2023, down 19% quarter-over-quarter.
- 2 funds opened new Processa Pharmaceuticals positions in Q2 2023 and 6 closed out, a net change of -4 holders.
- The largest Processa Pharmaceuticals buyer in Q2 2023 was Citadel Advisors, an estimated $167K added.
- The largest Processa Pharmaceuticals seller in Q2 2023 was Walleye Capital, an estimated $217K sold.
Based on aggregated 13F filings for Q2 2023.